Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.830
+0.040 (1.43%)
At close: Mar 13, 2026, 4:00 PM EDT
2.830
0.00 (0.00%)
After-hours: Mar 13, 2026, 8:00 PM EDT
Protalix BioTherapeutics Market Cap
Protalix BioTherapeutics has a market cap or net worth of $227.59 million as of March 13, 2026. Its market cap has increased by 29.90% in one year.
Market Cap
227.59M
Enterprise Value
206.40M
1-Year Change
29.90%
Ranking
Category
Stock Price
$2.83
Market Cap Chart
Since December 1, 1998, Protalix BioTherapeutics's market cap has increased from $11.80M to $227.59M, an increase of 1,828.75%. That is a compound annual growth rate of 11.45%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 12, 2026 | 224.40M | 54.97% |
| Dec 31, 2025 | 144.80M | 4.62% |
| Dec 31, 2024 | 138.40M | 6.54% |
| Dec 29, 2023 | 129.90M | 87.18% |
| Dec 30, 2022 | 69.40M | 83.11% |
| Dec 31, 2021 | 37.90M | -68.68% |
| Dec 31, 2020 | 121.00M | 148.46% |
| Dec 31, 2019 | 48.70M | 5.64% |
| Dec 31, 2018 | 46.10M | -50.11% |
| Dec 29, 2017 | 92.40M | 107.64% |
| Dec 30, 2016 | 44.50M | -56.29% |
| Dec 31, 2015 | 101.80M | -40.95% |
| Dec 31, 2014 | 172.40M | -52.64% |
| Dec 31, 2013 | 364.00M | -24.96% |
| Dec 31, 2012 | 485.10M | 14.93% |
| Dec 30, 2011 | 422.10M | -47.92% |
| Dec 31, 2010 | 810.50M | 58.46% |
| Dec 31, 2009 | 511.50M | 266.14% |
| Dec 31, 2008 | 139.70M | -45.71% |
| Dec 31, 2007 | 257.30M | 2,552.58% |
| Dec 29, 2006 | 9.70M | -21.77% |
| Dec 30, 2005 | 12.40M | 1,671.43% |
| Dec 31, 2004 | 700.00K | -41.67% |
| Dec 31, 2003 | 1.20M | 300.00% |
| Dec 31, 2002 | 300.00K | -57.14% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Sol-Gel Technologies | 247.10M |
| Canton Strategic Holdings | 240.08M |
| Humacyte | 239.32M |
| Eledon Pharmaceuticals | 230.12M |
| Keros Therapeutics | 228.33M |
| Achieve Life Sciences | 227.84M |
| Cartesian Therapeutics | 226.65M |
| Elicio Therapeutics | 225.43M |